1. Home
  2. RGCO vs ACIU Comparison

RGCO vs ACIU Comparison

Compare RGCO & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RGC Resources Inc.

RGCO

RGC Resources Inc.

N/A

Current Price

$21.64

Market Cap

225.0M

Sector

Utilities

ML Signal

N/A

Logo AC Immune SA

ACIU

AC Immune SA

HOLD

Current Price

$2.71

Market Cap

247.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RGCO
ACIU
Founded
1912
2003
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
225.0M
247.6M
IPO Year
2005
2015

Fundamental Metrics

Financial Performance
Metric
RGCO
ACIU
Price
$21.64
$2.71
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $8.54
AVG Volume (30 Days)
9.6K
★ 164.1K
Earning Date
11-18-2026
11-03-2026
Dividend Yield
★ 3.99%
N/A
EPS Growth
★ 11.21
N/A
EPS
★ 1.37
N/A
Revenue
★ $95,334,212.00
N/A
Revenue This Year
$15.70
$422.39
Revenue Next Year
$4.44
$377.85
P/E Ratio
$15.76
★ N/A
Revenue Growth
★ 12.63
N/A
52 Week Low
$20.55
$2.10
52 Week High
$27.17
$4.00

Technical Indicators

Market Signals
Indicator
RGCO
ACIU
Relative Strength Index (RSI) 56.11 54.02
Support Level $20.86 $2.58
Resistance Level $22.21 $2.97
Average True Range (ATR) 0.50 0.16
MACD 0.09 -0.00
Stochastic Oscillator 91.78 66.75

Price Performance

Historical Comparison
RGCO
ACIU

About RGCO RGC Resources Inc.

RGC Resources Inc is involved in the business of distribution and sale of natural gas to residential, commercial, and industrial customers within its service territory in Roanoke, Virginia, and its surrounding localities. The company also provides certain non-regulated services. The company relies on multiple interstate pipelines to transport natural gas. The company operates in three segments: Gas Utility, which is the key revenue generator; Investment in Affiliates this segment reflects the income generated through the activities of the Company's investment in MVP and Southgate projects and Parent & Other including the unregulated activities of the Company as well as certain corporate eliminations.

About ACIU AC Immune SA

AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: